Anti-CCR9-Antikörper

Details

Veröffentlichungs-Nr.

EP4578874

Aktenzeichen

EP23383408

Anmeldetag

29. Dezember 2023

Veröffentlichung

2. Juli 2025

Rechtsraum

EP

IPC

C07K16/28

Abstract

The present invention provides an anti-CCR9 antibody or antigen binding fragment thereof comprising a variable light chain comprising SEQ ID NO:1 or a variant thereof having at least 95% sequence identity to SEQ ID NO:1, wherein the variable light chain comprises a CDR-L1 comprising the amino acid sequence RSSQSLXHSNGXTFLH (SEQ ID NO: 2), a CDR-L2 comprising the amino acid sequence KVSNRFS (SEQ ID NO: 3) and a CDR-L3 comprising the amino acid sequence SQTTHXPWT (SEQ ID NO: 4), wherein X can be any amino acid. Also provided is the anti-CCR9 antibody or antigen binding fragment thereof for use in the treatment or prevention of a disease, as well as methods of diagnosis and antibody drug conjugates.

Anmelder

Firmen

SunRock Biopharma S.L.
TOHOKU UNIVERSITY

Land

🇪🇸 Spanien

Fachgebiete